Astragaloside IV promotes pharmacological effect of Descurainia sophia seeds on isoproterenol-induced cardiomyopathy in rats by synergistically modulating the myosin motor

Xingkai Liu1,2†, Qian Chen3†, Xuming Ji4†, Wanchen Yu3, Tong Wang3, Juanjuan Han1, Shumu Li2, Jianan Liu1, Fangang Zeng5, Yao Zhao1, Yanyan Zhang1, Qun Luo1,2* and Fuyi Wang1,2,3*

1Beijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, National Centre for Mass Spectrometry in Beijing, CAS Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China, 2University of Chinese Academy of Sciences, Beijing, China, 3College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China, 4Academy of Chinese Medical Science, School of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China, 5School of Environment and Natural Resources, Renmin University of China, Beijing, China

Descurainia sophia seeds (DS), Astragalus mongholicus (AM), and their formulas are widely used to treat heart failure caused by various cardiac diseases in traditional Chinese medicine practice. However, the molecular mechanism of action of DS and AM has not been completely understood. Herein, we first used mass spectrometry coupled to UPLC to characterize the chemical components of DS and AM decoctions, then applied MS-based quantitative proteomic analysis to profile protein expression in the heart of rats with isoproterenol-induced cardiomyopathy (ISO-iCM) before and after treated with DS alone or combined with AM, astragaloside IV (AS4), calycosin-7-glucoside (C7G), and Astragalus polysaccharides (APS) from AM. We demonstrated for the first time that DS decoction alone could reverse the most of differentially expressed proteins in the heart of the rats with ISO-iCM, including the commonly recognized biomarkers natriuretic peptides (NPPA) of cardiomyopathy and sarcomeric myosin light chain 4 (MYL4), relieving ISO-iCM in rats, but AM did not pronouncedly improve the pharmacological efficiency of DS. Significantly, we revealed that AS4 remarkably promoted the pharmacological potency of DS by complementarily reversing myosin motor MYH6/7, and further downregulating NPPA and MYL4. These findings not only provide novel insights to better understanding in the combination principle of traditional Chinese medicine but also highlight the power of mass spectrometry in exploring the molecular mechanisms of herbal medicines.
s spectrometric proteomics strategy combined with conventional pathological approaches for the traditional medicine research.

**KEYWORDS**

astragaloside IV, cardiomyopathy, myosin, quantitative proteomics, *Descurainia sophia* seed, traditional Chinese medicine

**Introduction**

Cardiomyopathy is one of the leading causes of heart failure, and dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are the two most common cardiomyopathies (Yamada and Nomura, 2021). HCM is a genetic disease, to which hundreds of mutations in genes encoding cardiac myosin and sarcomere-related proteins are linked (Lehman et al., 2022). However, various factors, such as ischemia, viral infection, and alcohol toxicity, could cause DCM, though the variants in genes encoding sarcomeric proteins, for example, myosin heavy chain-β and -α (MYH7 and MYH6), and the myosin light chain MYL2 were also implicated in DCM (Kamisago et al., 2000; Yuan et al., 2018). Sarcomeric myosins act as the molecular accelerator/brake, modulating cardiac contractility (Daniels et al., 2021). The inherited HCM and DCM are both attributable to pathogenic variants in the myosin motor, which alters the proportion of the myosin accelerator and brake (Daniels et al., 2021). Therefore, directly targeting sarcomere in genetic cardiomyopathies has been thought to be a root-eradicating strategy for the treatment of these diseases without side effects on other organs. Both myosin activators and inhibitors have been developed and shown great promise for therapeutics of HCM and/or DCM (Lehman et al., 2022). For example, danicamtiv, a promising cardiac myosin activator, also known as MYK-491, was reported to selectively promote cardiac actomyosin activity by increasing myosin head availability and phosphate release rates (Shen et al., 2021), reversing respective contractile disorder in engineered heart tissue models of HCM and DCM (Halder et al., 2021). In contrast, mavacamten, a myosin inhibitor, also known as MYK-461, was shown to reduce sarcomere contractility in HCM by binding to myosin and decreasing phosphate release rates (Anderson et al., 2018; Lehman et al., 2022).

Traditional Chinese medicines (TCMs) have been used for long time to treat cardiac diseases including DCM and HCM (Yu et al., 2019; Li et al., 2020; Tan et al., 2020). Among them, *Descurainia sophia* seeds (DS; Brassicaceae; *Descurainia sophia* (L.) Webb ex Prantl. seed) and *Astragalus mongholicus* Bunge (AM; Leguminosae; *Astragalus mongholicus* Bunge radix) and their combination are widely used to treat heart failure caused by various cardiac diseases (Ma et al., 1998; Chen et al., 2006a; Zhou et al., 2016; Yu et al., 2019; Liu et al., 2020; Huang et al., 2021; Yu et al., 2021). Quercetin and kaempferol were identified by a network pharmacology study, to be the main active components in the DS–AM formula. They were believed to relieve heart injury by regulating PI3K-Akt, VEGF, and erbB signaling pathways, and insulin resistance (Yu et al., 2021). Quercetin is one of the active flavone components in many Chinese herbal medicines. Our pharmacological studies showed that DS decoction could alleviate heart failure by inhibiting excessive activation of the neuroendocrine system, strengthening myocardial contractility, and reducing end-diastolic volume and pressure to improve cardiac hemodynamics. However, quercetin alone produced less pharmacological effect than DS used in the whole (unpublished data). In TCM practices AM is believed to be an important Qi tonic medicine and can replenish Qi and Yang, promoting diuresis and detumescence and enhancing myocardial muscle strength. More studies on the mechanism of action of AM, in particular the three major active components astragaloside IV (AS4) (Liu et al., 2018; Lin et al., 2019; Tan et al., 2020; Zang et al., 2020), calycosin-7-glucoside (C7G), and Atragralus polysaccharides (APS), have also been reported. The major bioactive components astragalosides, in particular astragaloside IV (AS4), from AM have been extensively studied (Zhang et al., 2015; Xu et al., 2016; Tan et al., 2020; Du et al., 2022) were shown to exert a beneficial effect on myocardial lesion by regulating ATP consumption and preserving intracellular Ca²⁺ homeostasis (Chen et al., 2006b). Wang et al. reported that AS4 reduced cardiac hypertrophy induced by aortic banding surgery in mice via inactivating the TBK1/PI3K/AKT signaling pathway (Liu et al., 2018). Zhang et al. (2015) demonstrated that AS4 released ISO-induced cardiac hypertrophy via regulating NF-κB/PGC-1α signaling and improved the ISO-induced vascular dysfunction by regulating eNOS uncoupling-mediated oxidative stress and retarding ROS-NF-κB signaling (Xu et al., 2016). Xiao et al. showed that AS4 acting as an antioxidant relieved doxorubicin-induced cardiomyopathy in vitro and in vivo by suppressing NADPH oxidase expression (Lin et al., 2019). AS4 was also revealed to ameliorate isoprenaline-induced cardiac fibrosis in mice by modulating gut microbiota and fecal metabolites (Du et al., 2022). Calycosin is another major active component in AM and was shown to attenuate oxidative stress-induced cardiomyocyte apoptosis by activating estrogen receptors and promoting AKT phosphorylation (Liu et al., 2016). Very recently, calycosin was reported to act as a PI3K activator to ameliorate inflammation and fibrosis in heart failure via the AKT-IKK-STAT3 axis (Wang et al., 2022). Atragralus polysaccharide was revealed to be able to inhibit diabetic cardiomyopathy in hamsters by suppressing chymase activation (Chen et al.,
2010a; Chen et al., 2010b). However, despite DS and AM and their active components have been extensively studied, the molecular mechanism of action of them has not been completely understood. For instance, how DS and AM or their active components regulate PI3K/AKT phosphorylation signaling pathway? How DS and AM or their active components regulate ATP consumption and maintain intracellular Ca$^{2+}$ homeostasis?

To address these issues, in the present work, we applied a mass spectrometry (MS)-based quantitative proteomics strategy to explore the mechanism of action of DS combined with AM or the major active components, astragaloside IV and calysosin-7-glucoside, of AM. The studies were performed on rats with isoproterenol-induced cardiomyopathy (ISO-iCM) (Xie et al., 2015). With quantitatively comparing the protein expression levels in the heart of the sacrificed control, model, and treated rats, we demonstrated for the first time that DS decoction ameliorates ISO-iDM in rats by significantly downregulating the typical biomarkers of cardiomyopathy, including natriuretic peptides A (NPPA) and myosin light chain 4 (MYL4) (Tripathi et al., 2017). More importantly, we provided molecular evidence for that AM did not improve the pharmacological effect of DS on ISO-iDM, but astragaloside IV (AS4) in AM remarkably promoted the pharmacological efficacy of DS by reversing the expression of the sarcomeric motor myosin heavy chain 7 (MYH7) (Daniels et al., 2021), and further downregulating NPPA and MYL4. The combination of DS with AS4 interestingly showed a similar beneficial effect on cardiac contractibility to the myosin inhibitor mavacamten under clinical trial (Anderson et al., 2018; Lehman et al., 2022).

### Materials and method

#### Reagents

**Descurainia sophia** seeds (DS; Brassicaceae; *Descurainia Sophia* (L.) Webb ex Prantl. seed) and **Astragalus mongholicus Bunge** (AM; Leguminosae; *Astragalus mongholicus Bunge* radix) were purchased from Baiweitang Decoction Pieces Co. (China). The two plant materials were identified by the affiliated hospital of Shandong University of Traditional Chinese Medicine, with Specimen Nos. SUTCM/PHAR/HBB/21/05/17 and SUTCM/PHAR/HBB/20/03/18, respectively. Astragalus polysaccharides (P/N: 7105MC, w/w 99%) was provided by Medicass Biological Products Co. (China). Astragaloside IV and calycosin-7-glucoside were obtained from Nature Standard Technical Service Co. (China). The low protein binding microcentrifuge tube was purchased from Thermo Fisher Scientific Ltd. (United States). Sodium chloride obtained from Sinopharm Chemical Reagent Co., Tris base from BioDee (China), and Tween-20 from Solarbio (China) were used to prepare TBST buffer. HPLC grade water (Fisher Chemical) was used throughout all experiments.

#### Animals and models

In primary experiments, we did not find significant difference in the pharmacological efficiency of DS and AM and various combinations between male and female rats with isoproterenol-induced cardiomyopathy (ISO-iCM). Therefore, in the present work, we selected 1:1 of male and female rats to establish of ISO-iCM models. To this end, 77 specific-pathogen-free, Sprague–Dawley rats (half male and half female), weighing 260 ± 20 g, were purchased from Beijing Vital River Laboratory Animal Technology Co. Ltd (Beijing, China), with a certification number of SCXK (jing) 2012-0001. The rats were acclimated for 3 days in the animal facility of the Shandong University of Traditional Chinese Medicine and then randomly divided into seven groups, designated as control group (CG), model group (MG), and treated groups with DS decoction alone (DS), DS combined with AM (DSAM), astragaloside IV (DSAS4), calycosin-7-glucoside (DSC7G), or Astragalus polysaccharides (DSAPS) decoction, respectively, with 11 rats in each group. Isoproterenol was used to induce cardiomyopathy, following the procedure reported previously (Xie et al., 2015). In brief, isoproterenol (3 mg kg$^{-1} \cdot$day$^{-1}$) was subcutaneously injected into the scapular region of each rat for 10 days. After 2 weeks of observation, an endotracheal tube was implanted in each rat by using an endotracheal intubation device. The catheter was retained for 7 days prior to further experiments. Notably, the endotracheal tube was used to establish the models with the Upper Energizer Stage patterns (Code: SG70 in the International Statistical Classification of Diseases and Related Health Problems (ICD-11)) with the fluid disturbance pattern (ICD Code: SF11), accompanied with isoproterenol stimulus. However, in the present work, the pharmacological benefits of all formulas were evaluated only based on the heart of the models. All animal experiments were approved by the Ethics Committee of Shandong University of Traditional Chinese Medicine and carried out in accordance with the Laboratory Animal-Guideline for Ethical Review of Animal Welfare (GB/T 35892-2018).

#### Preparation and administration of drugs

The DS and AM decoctions were prepared following the traditional clinical medication method described in Chinese Pharmacopoeia (2010 Edition, p283 and p313). In brief, an aliquot of purchased DS seeds and AM slices were individually put into a casserole, followed by the addition of 10-fold tap water to obtain a final concentration of 0.18 g/ml for DS and 0.54 g/ml for AM, and stilled at room temperature for 0.5 h and then boiled for 1 h. The raw decoction was filtered, and...
the filtrate was collected. The boiling and filtration were repeated three times, and the filtrates were merged. The merged decocations were evaporated to the initial values, of which the final concentrations of total extracts were 2.18 mg/ml (DS) and 6.53 mg/ml (AM), respectively. The mixed decocion of DS and AM (1:3, w/w) was prepared following the procedure described earlier, of the final concentration of total extract was 8.73 mg/ML. Aliquots of AS4, C7G, and APS were individually dissolved in 0.5% sodium carboxymethyl cellulose solution to prepare the suspensions of 3 mg/ml for AS4, 1.5 mg/ml for C7G, and 141 mg/ml for APS, which were stored at 4°C before use.

After pathological assessments of all rats with ISO-iDM, DS decocion and the various combinations were administrated. Based on the Chinese Pharmacopoeia (2010 Edition), 10 ml kg\(^{-1}\) of DS decocion (containing 21.8 mg of extract in total) was administrated to each rat of the DS group, 10 ml kg\(^{-1}\) of mixed decocion of DS and AM (containing 87.3 mg of extract in total) to each rat of the DSAM group, and 10 ml kg\(^{-1}\) of DS decocion plus 50 mg kg\(^{-1}\) of AS4, 30 mg kg\(^{-1}\) of C7G, or 41 mg kg\(^{-1}\) of APS, were administrated to each rat of the DSAS4, DSC7G, or DSAPS group, respectively, by gavage once a day for 14 days. While the rats in the control and model groups were given normal saline at the same dose.

Characterization of components in *Descurainia sophia* seeds and *Astragalus mongholicus*

**Preparation of *Descurainia sophia* seeds (DS) and *Astragalus mongholicus* (AM) samples**

Aliquot (100 μL) of DS or AM decocion prepared as described earlier was diluted by 900 μL method chloroform (3:2) mixture, and then 200 μL deionized water was added. The resulting mixture was centrifuged at 15,000 g, 4°C for 15 min. The up-layer was then transferred to a new tube and dried in a vacuum centrifuge. The residue was re-dissolved by 150 μL 80% MeOH/H\(_2\)O containing 0.25% formic acid (FA) and 80% MeOH/H\(_2\)O containing 20 mM ammonium acetate for positive and negative ESI-MS/MS analyses, respectively.

**UPLC–MS/MS**

The UPLC–MS/MS characterization of components in DS and AM decocations was performed on a SYNAPT XS mass spectrometer coupled with the Waters ACQUITY Class I UPLC PLUS and an ACQUITY UPLC\(^*\) HSS T3 column (i.d. 1.8 μm, 100 mm × 2.1 mm) (Waters, United States). The mobile phases were water containing 0.25% FA (A) and methanol containing 0.25% FA (B) for positive mode, and water containing 20 mM ammonium acetate (A) and methanol containing 20 mM ammonium (B) for negative mode, respectively. For both positive and negative detections, the mobile phase B started at 2% and increased to 5% at 1 min, and further increase to 45% at 7 min, to 85% at 10 min, and to 95% at 17 min, with a flow rate of 0.17 ml/min.

The mass spectrum data were collected in HDMS\(_x\) mode, and the detection parameters were set as follows: acquiring mass range from 95-1000 Da under sensitivity acquisition mode; scan time 1.5 s; low transfer collision energy 15 V; and high ramp transfer collision energy 60–80 V. The lock-mass compound was leucine enkephalin (0.2 ng/ml).

**Data analysis**

Progenesis QI was used to interpret MS raw data. The mixture of DS and AM (1:1) decocion was used to align the chromatographic peaks for each mass spectrum file. For positive ion detection, the adduct ions including [M + H]\(^+\), [M + Na]\(^+\), [M + K]\(^+\), [M-H\(_2\)O + H]\(^+\), and [M+2H]\(^2+\) were selected. The adduct ions [M-2H]\(^-\), [M-H\(_2\)O-H]\(^-\), [M-H]\(^-\), and [M + Cl]\(^-\) were selected for the negative mode. The compounds which have the highest abundance in the blank group or Anova(p) value larger than 0.0001 were filtered out for future analysis. KEGG, Human Metabolome Database, BroadPharm, Food and Agriculture Organization, xPharm, AQ BioPharma, AxisPharm, BL Dpharm, abcr, and PubMed metabolite databases, and Nature Chemical Biology, Nature Chemistry, Nature Communications, and Springer Nature databases, were used to identify compounds detected by MS. The precursor tolerances and fragmentation tolerances were set 10 and 5 ppm, respectively. After identification, the compounds with Anova(p) value < 0.0001, abundance > 5000, and abundance ratio between AM and DS > 25 or < 0.04 were considered as the main contents for AM and DS, respectively.

**Echocardiography**

After the intervention described earlier, rats in all groups were examined by high-frequency echocardiography with a pb207 probe (20 MHz). The left ventricular ejection fraction (LVEF) and the left ventricular short-axis shortening fraction (LVFS) were measured by ultrasonic measurement.

**Determination of cardiac index and left ventricular mass index**

Rats were weighed, then injected intraperitoneally with 10% chloral hydrate (3 ml/kg), anesthetized, and fixed. Blood was collected from the main abdominal vein and placed in an anticoagulant tube at room temperature for 2 h, centrifuged at 4°C, and 4,000 g for 10 min. The supernatant was stored at −80°C for determination of the creatine kinase (CK) level by enzyme-linked immunosorbent assay kit (Jiancheng Bioengineering
Institute, China). Then, the rats were sacrificed to remove hearts, which washed off the residual blood with 0.9% ice normal saline, dried with filter paper, and weighed. The left atrium was cut off along the coronary sulcus, and the right ventricle was removed along the interventricular sulcus. The left ventricular was weighed, and the cardiac index (cardiac weight/body weight, HWI) and left ventricular weight index (left ventricular weight/body weight, LVWI) were thereby calculated.

Histopathological assays

The left ventricular myocardial tissue of each rat was fixed with 10% paraformaldehyde for 24 h and then embedded in paraffin. The tissue sections were stained with hematoxylin–eosin and Masson (Wuhan Google Biotechnology, China) for pathological assays on a Nikon Eclipse optical microscope (Nikon, Japan). The collagen fiber volume fraction (CVF) of Masson’s stained sections was calculated by the ipp6.0 image analysis system (Media Cybernetics).

Quantitative proteomics analysis

The workflow of quantitative proteomics analysis is shown in Figure 1, and the detailed procedures are described as follows.

Protein extraction and digestion

RIPA lysis buffer (Beyotime, China) was added to ca. 0.5 g of rat heart tissue at 100 µL:10 mg ratio, the tissue was then lysed for 30 s by a homogenate machine (JXFSTPRP-24, Shanghai Jingxin Industrial Development Co., Ltd.) at 50% pulse for 5 times. The raw protein extract was centrifuged at 12,000 g for 15 min, and then the supernatant was transferred to a PE tube. After the measurement of protein concentration by BCA kit (Beyotime), an aliquot (100 µg) of each extract was transferred to a 10 kD centrifugal filter (Merck Millipore), and 200 µL of 0.1 M triethylammonium bicarbonate (TEAB, Thermo Scientific) buffer was added to wash off lysis buffer twice at 14,000 g for 30 min at 4°C. Thereafter, 50 µL of 0.5 M TEAB was used to re-dissolve the protein residues in the ultrafilter, and then the proteins were denatured and reduced by incubating in a buffer, containing 0.1% SDS, 5.3 mM TCEP, and 0.5 M TEAB for 1 h at 60°C, followed by alkylation of cysteinyl thiols with 3 µL of 200 mM MMTS at 25°C for 15 min. The excess of denaturing, reducing, and alkylation reagents were washed off by centrifuging twice at 14,000 g for 30 min at 4°C. Then, the supernatant was supplemented with 200 µL of 0.1 M TEAB buffer, and the protein residue was re-dissolved with 30 µL of 0.5 M TEAB and digested by adding 2 µL of 1 µg/µL MS grade rAc-Trypsin (Bei-Er-Li, China) and incubating at 37°C for 16 h. The resulting tryptic peptides were collected by adding 200 µL 0.1 M TEAB buffer into the 10-kD centrifugal filter, spinning at 14,000 g for 30 min at 4°C, followed by desalting by a C18 cartridge (Waters Sep-Pak). The C18 cartridge was first
activated by 1 ml of 0.1% formic acid (Honeywell Fluka™)/80% acetonitrile (Fisher Chemical) and 1 ml of 0.1% formic acid (FA)/50% acetonitrile (ACN) sequentially, and then equilibrated by 1 ml of 0.1% trifluoroacetic acid (Alfa Aesar) twice. The collected peptides were loaded into the equilibrated column and washed twice with 1 ml of 0.1% trifluoroacetic acid (TFA), and then eluted with 1 ml of 0.1% FA/50% ACN and 1 ml of 0.1% FA 80% ACN sequentially. Finally, the desalted peptides were merged and dried in a vacuum centrifuge for further use.

**iTRAQ labeling**

Each desalted peptide mixture was re-dissolved in 20 µL of 0.5 M TEAB buffer, and mixed with 70 µL of iTRAQ labeling reagent (SCIEX) dissolved in isopropanol (Cairn Pharmaceutical Technology Co.). The resulting mixture was adjusted to pH = 7.6 and then incubated at room temperature for 2 h. The labeling reaction was then quenched by adding 150 µL of deionized water and incubating for 15 min at room temperature. Thereafter, each labeled peptide mixture with different isotopic patterns from six groups were equivalently mixed and desalted by a C18 cartridge again following the same procedure described earlier.

**HPLC pre-fractionation**

The labeled and desalted peptide mixture was dried by vacuum centrifuge, and then re-dissolved in 100 µl. 4.5 mM ammonium formate in 2% ACN aqueous solution (pH 10). An aliquot (95 µl) of each labeled peptide mixture was loaded into HPLC (Agilent Technologies 1260 infinity) with a C18 column (CAPCELL PAK MG II S-5, 4.6 × 150 mm, 5 µm, Shiseido), and eluted by basic (pH = 10) mobile phases A (4.5 mM HCOONH4 in 2% ACN) and B (4.5 mM HCOONH4 in 90% ACN). The gradient started with 0% B until 9 min and continuously increased to 6% B at 13 min, 28.5% B at 63 min, 34% B at 68.5 min, 60% B at 81.5 min, and maintained until 90 min with a flow rate of 1 ml/min. The fractions were collected chronologically into 12 tubes from 3 to 90 min, individually lyophilized and re-dissolved in 10 µL of 0.1% formic acid for NanoLC–MS/MS analysis.

**NanoLC–MS/MS analysis**

The NanoLC–MS/MS analysis was performed on an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific) coupled with an EASY-nLC 1200 nanoHPLC system equipped with an Acclaim™ PepMap™ 100 pre-column (20 mm × 75 µm, 3 µm) and an Acclaim™ PepMap™ RSLC C18 analytical column (150 mm × 75 µm, 2 µm). The mobile phases for the NanoLC separation were 0.1% FA in H2O (A) and 80% ACN/20% H2O (B), respectively, with a flow rate of 300 nL/min. The mobile phase B started at 2% and increased to 6% at 1 min, and then to 30% at 85 min, 60% at 94 min, and sharply to 90% within 1 min and remained at 90% for 5 min, and then decreased to 50% within 1 min and remained at 50% for 9 min, finally dropped down to 2% within 1 min and remained 3 min. An aliquot (1 µL) of each HPLC fraction containing 0.1% formic acid was loaded, and elution from the analytical column was directly infused into the mass spectrometer for MS/MS analysis. The details of the parameters of the MS/MS analysis are listed in Supplementary Table S1.

**Protein identification and quantification**

Acquired MS/MS spectra were analyzed by Proteome Discoverer 2.2 (Thermo Fisher Scientific) to identify and quantify proteins based on the protein database (Version 10/25/2017, 42,252 sequences) downloaded from the UniPort database. The taxonomy was Rattus norvegicus, and the taxon identifier was 10116. Sequest HT 2.2 search engine was used for peptide matching. The dynamic modifications were oxidation at methionine and phosphorylation at serine and threonine. The static modifications were carbamidomethylation at cystine, iTRAQ labeling at lysine, tyrosine, and N-terminus of all peptides. The quantitative results were normalized based on the abundance of total peptides in each set. Abundance ratios were calculated for each protein identified in all groups other than controls by comparing the value of each protein to that of the same protein in the control group. The other settings are the defaults of PD software.

**Western blotting**

The expression levels of the NPPA, TPM1, and TPM2 in the control and model groups were measured by Western blotting with glyceraldehyde phosphate dehydrogenase (GAPDH) as an internal control protein. An aliquot (40 µg) of protein extract from the heart tissue of each group was boiled at 95°C for 5 min in SDS-loading buffer and separated over 4–12% polyacrylamide gel (GeneScript) at 140 V for 1 h with Tris-MOPS-SDS running buffer (GeneScript). The proteins were then transferred to the PVDF membrane by semi-dry transfer blotting at 20 V for 1 h. The PVDF membrane (Millipore) with proteins was cut into two parts along ca. 30 kD, and then blocked in 5% milk TBST buffer for 120 min. Anti-NPPA antibody (Abcam), anti-TPM2 (Abcam), anti-TPM1 (Abcam), and anti-GAPDH (Abcam) were diluted at 1:1000, 1:300, 1:1000, and 1:5000, respectively, to blot PVDF membrane by incubation at 4°C for 10 h, and then washed three times by 5% milk TBST for 5 min each. The PVDF membrane was then incubated with horseradish peroxidase-conjugated secondary antibodies, goat antirabbit antibody (Abcam) for NPPA, TPM2, and TPM1 and goat antimouse antibody (Abcam) for GAPDH, respectively, for 1 h at 25°C. After washing with TBST, the protein bands were visualized by enhanced chemiluminescence (Tanon 5200 Multi, China), and the optical densities were quantified using ImageJ.
Bioinformatics analysis

The proteins identified and quantified by MS/MS, of which false-discovery rates (FDRs) are <0.01, p-values <0.05, and abundance ratios (model vs. control) ≥ 1.5 or ≤ 0.67, were uploaded into the STRING 10.0 data pool for Gene Ontology (GO) and protein–protein interaction (PPI) network analysis. The UniProt accession ID of the differentially expressed proteins (DEPs) in the heart tissues of the model and treated groups were inputted into the list of gene name box, and Rattus norvegicus organism was selected for the analysis. The confidence option was selected for the meaning of network edge, and textmining, experiments, databases, co-expression, neighborhood, gene fusion, and co-occurrence options were chosen for active interaction sources.

Statistical analysis

All data were analyzed with Origin 8.0 and Microsoft Office Excel 2010 software and are expressed as mean ± SEM. The between-group differences in physiological and/or pathological indexes were analyzed by one-way ANOVA. A two-sided p value <0.05 represents statistically significant. * indicates p < 0.05, **p < 0.01, and ***p < 0.001. Principal component analysis (PCA) was performed on MATLAB(Version 8.4.0.150421, MathWorks Inc.).

Results

Characterization of components in Descarainia sophia seeds and Astragalus mongholicus

To investigate the mechanism of action of Descarainia sophia seeds (DS) and Astragalus mongholicus (AM), we first characterize the main components in DS and AM decoctions, individually, by UPLC–MS/MS. As shown in Supplementary Figure S1, both the decoctions display complicated composition. We collected all ion peaks detected by MS in DS and AM decoctions under both positive and negative modes into the Progenesis QI program for principal component analysis (PCA). In total, 10,078 positive ion peaks and 6,710 negative ion peaks were selected by Progenesis QI. The results showed that under the positive mode, the first principal component (PC1) can distinguish DS and AM, and under the negative mode, the second principal component (PC2) can separate DS and AM (Supplementary Figure S2). The 10,078 positive ion peaks and 6,710 negative ion peaks enabled the identification of 90 compounds commonly existing in DS and AM decoctions, of which the abundance (A) ratios calculated on $A_{DS}/A_{AM}$ or $A_{AM}/A_{DS}$ are >1 and <25 (Supplementary Figure S2). Furthermore, after data filtering, 48 and 23 compounds were exclusively identified for DS with the $A_{DS}/A_{AM}$ values > 25, and for AM with the $A_{AM}/A_{DS}$ >25, respectively (Tables 1, 2, Supplementary Tables S3, S4). The identification was verified further by checking the MS$^2$ fragment patterns and the isotope similarity of each compound to the standard. For example, one of the main components in DS is quercetin-7-O-β-D-glucopyranosyl (1→6)-β-D-glucopyranoside (Figure 2A), according to the integrative pharmacology-based network computational research platform of traditional Chinese medicine database (TCMIP v2.0, http://www.tcmip.cn/). The hydrolytic product of this component, quercetin (Figure 2B), was identified under positive mode with a retention time of 7.66 min at the extraction chromatogram (EIC) (DS-11 in Supplementary Figure S3A), and the fragment pattern is depicted in Supplementary Figure S4A, which shows that the MS/MS fragments of quercetin were observed at $m/z$ 153.0183, 121.0284 and 137.0234, being consistent with Makarov’s report (Scigelova et al., 2011). The well-known major component in AM, astragaloside IV (Figure 2C), was detected at 13.13 min (AM-23 in Supplementary Figure S3C), of which the MS/MS fragment ions were detected at $m/z$ 669.3967, 627.3853, and 203.0526 (Supplementary Figure S4B).

Phenotypic and pathological characterization of isoproterenol-induced cardiomyopathy in rats

Isoproterenol (ISO) as a β-adrenergic receptor (β-AR) agonist is often used to induce cardiomyopathy in the mouse (Shanmugam et al., 2019; Houson et al., 2020; Zhu et al., 2020). We have previously constructed rat models with the upper energizer stage (ICD code: SG70) and fluid retention patterns (ICD code: SF11) by injecting subcutaneously into the abdomen of rats, accompanied by the endotracheal intubation. The established models included disorders in both the heart and lung of rats (Xie et al., 2015). We have also primarily evaluated the effects of DS, AM, and DS/AM formula on the lung and heart functions of the model rats and found that the combined use of DS with AM produced better pharmacological effects on the lung and cardiac functions evidenced by the reversion of the lung weight index (LWI), the lung permeability index (LPI), left ventricular weight index (LVWI), and left ventricular ejection fraction (LVEF) (Chen et al., 2019). In the present work, we only evaluate the phenotypes and pharmacological benefits of DS and AM as well as each combination on the disorders in the heart of the rat models induced by isoproterenol.

As echocardiographic left ventricular ejection fraction (LVEF) and left ventricular fraction shortening (LVFS) accurately reflect the cardiac function, for example, systolic and diastolic functions (Cho et al., 2018; Rieth et al., 2019), we first performed a high-frequency echocardiographic
| Compound no. | Accepted description | Retention time/min | m/z | Adducts | Formula | Abundance | Fold change |
|-------------|----------------------|--------------------|-----|---------|----------|-----------|-------------|
| DS-1        | (5Z)-3-Ethyl-5-[(4-(4-fluorobenzoyloxy) benzylidene)-2-thioxo-1,3-thiazolidin-4-one] | 3.82 | 372.0534 | M-H | C_{19}H_{16}FNO_2S_2 | 2306842 | 120.8 |
| DS-2        | 1-[(Benzylcarbonyl)-3-(carboxymethyl)-3- pyrrolidinedicarboxylic acid] | 7.04 | 308.1125 | M + H | C_{19}H_{19}O_4 | 1018277 | 31.0 |
| DS-3        | 1-Nitro-7-hydroxy-8-glutathionyl-7,8- dihydrodronaphthalene | 10.30 | 477.1080 | M-H, 2O-H | C_{20}H_{24}N_4O_9S | 963011 | 162.1 |
| DS-4        | (8Z,22Z)-4-Methoxy-2-oxa-11,20,21,24,27-tetraocta-10,21-dione | 5.68 | 472.1168 | M + Na | C_{20}H_{23}NO_4S | 875325 | 2199.6 |
| DS-5        | Methyl 5-[(4-carbamoyl-2,6-dimethyl-N-[(2-methyl-2-propanyl)oxy]carbonyl-L-phenylalanyl)-(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino methyl]-2-methoxybenzoate | 8.94 | 718.3035 | M + Cl | C_{38}H_{45}N_5O_7 | 841332 | 2231.0 |
| DS-6        | 1-(1-Ethyl-1H-pyrrol-3-yloxy)-7,7-di- fluoro-2-azaspiro[3.5]nonane | 9.87 | 289.1266 | M + Cl | C_{14}H_{20}F_2N_2 | 831149 | 1688.2 |
| DS-7        | Nepetin | 7.79 | 317.0653 | M + H | C_{16}H_{12}O_7 | 803804 | 1688.2 |
| DS-8        | (8E,22E)-4-Methoxy-2-oxa-11,16,20-triaxatricyclo[22.2.2.1–3.7]nonacosa-1(26),3(29),4,6,8,22,24,27-tetraocta-10,21-dione | 5.68 | 472.1168 | M + Na | C_{20}H_{23}NO_4S | 875325 | 2199.6 |
| DS-9        | (3-Isopropoxy-2-thienyl) (phenyl)methanol | 8.27 | 317.0653 | M + H | C_{15}H_{10}O_6 | 722166 | 33.8 |
| DS-10       | Ethyl 3-amino-5-methoxy-4.5,6,7-tetrahydro-1-benzofuran-2-carboxylate | 10.31 | 287.0550 | M + H | C_{15}H_{10}O_6 | 315159 | 25.8 |
| DS-11       | 1,2-indandione | 6.16 | 146.0589 | M + H | C_{9}H_{7}NO | 308144 | 58.1 |
| DS-12       | 4(1H)-Isoquinolinone | 9.56 | 777.2218 | M + H | C_{21}H_{24}N_2O_5S | 272640 | 280.6 |
| DS-13       | Kaempferol | 7.04 | 262.1069 | M + Na | C_{12}H_{17}NO_4 | 323375 | 33.0 |
| DS-14       | 4,4-Di- fluoro-2-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)cyclopentanecarboxylic acid | 7.66 | 303.0493 | M + H | C_{10}H_{6}O_3 | 503905 | 203.8 |
| DS-15       | HYPO-3,5-D-glucopyranose | 7.66 | 291.0898 | M-H, 2O-H | C_{14}H_{18}O_7 | 205788 | 3514.0 |
| DS-16       | 1,2-indandione | 8.94 | 427.1389 | M + K | C_{19}H_{24}N_4O_5S | 122759 | 85.2 |
| DS-17       | 1-O-trans-cinnamoyl-D-glucopyranose | 7.66 | 287.0550 | M + H | C_{16}H_{12}O_7 | 315159 | 25.8 |
| DS-18       | 1,2-indandione | 8.94 | 291.0898 | M + H | C_{16}H_{12}O_7 | 205788 | 3514.0 |
| DS-19       | Hexamethyoxime | 8.94 | 381.1330 | M + H | C_{16}H_{12}O_7 | 196306 | 29.1 |
| DS-20       | 2-Methyl-2-propyl-[5-(6-hydroxy-2-naphthyl]-2,2-dimethoxy-1,3-dioxan-5-yl]carbamate | 8.94 | 247.0778 | M + H | C_{16}H_{12}O_7 | 190240 | 257871.9 |
| DS-21       | 2-Methyl-2-propyl-[5-(6-hydroxy-2-naphthyl]-2,2-dimethoxy-1,3-dioxan-5-yl]carbamate | 8.94 | 247.0778 | M + H | C_{16}H_{12}O_7 | 190240 | 257871.9 |
| DS-22       | 2-Methyl-2-propyl-[5-(6-hydroxy-2-naphthyl]-2,2-dimethoxy-1,3-dioxan-5-yl]carbamate | 8.94 | 247.0778 | M + H | C_{16}H_{12}O_7 | 190240 | 257871.9 |
| DS-23       | 2-Methyl-2-propyl-[5-(6-hydroxy-2-naphthyl]-2,2-dimethoxy-1,3-dioxan-5-yl]carbamate | 8.94 | 247.0778 | M + H | C_{16}H_{12}O_7 | 190240 | 257871.9 |
| DS-24       | 2-Methyl-2-propyl-[5-(6-hydroxy-2-naphthyl]-2,2-dimethoxy-1,3-dioxan-5-yl]carbamate | 8.94 | 247.0778 | M + H | C_{16}H_{12}O_7 | 190240 | 257871.9 |
| DS-25       | 2-Methyl-2-propyl-[5-(6-hydroxy-2-naphthyl]-2,2-dimethoxy-1,3-dioxan-5-yl]carbamate | 8.94 | 247.0778 | M + H | C_{16}H_{12}O_7 | 190240 | 257871.9 |
| DS-26       | 2-Methyl-2-propyl-[5-(6-hydroxy-2-naphthyl]-2,2-dimethoxy-1,3-dioxan-5-yl]carbamate | 8.94 | 247.0778 | M + H | C_{16}H_{12}O_7 | 190240 | 257871.9 |
| DS-27       | 2-Methyl-2-propyl-[5-(6-hydroxy-2-naphthyl]-2,2-dimethoxy-1,3-dioxan-5-yl]carbamate | 8.94 | 247.0778 | M + H | C_{16}H_{12}O_7 | 190240 | 257871.9 |
| DS-28       | 2-Methyl-2-propyl-[5-(6-hydroxy-2-naphthyl]-2,2-dimethoxy-1,3-dioxan-5-yl]carbamate | 8.94 | 247.0778 | M + H | C_{16}H_{12}O_7 | 190240 | 257871.9 |
| DS-29       | 2-Methyl-2-propyl-[5-(6-hydroxy-2-naphthyl]-2,2-dimethoxy-1,3-dioxan-5-yl]carbamate | 8.94 | 247.0778 | M + H | C_{16}H_{12}O_7 | 190240 | 257871.9 |
| DS-30       | 2-Methyl-2-propyl-[5-(6-hydroxy-2-naphthyl]-2,2-dimethoxy-1,3-dioxan-5-yl]carbamate | 8.94 | 247.0778 | M + H | C_{16}H_{12}O_7 | 190240 | 257871.9 |

*Continued on following page*
examination on rats in all groups. As shown in Supplementary Figure S5, significant changes were observed between the ventricular cavity size and wall motion coordination of the heart of rats in the control group and model group. Compared with the control group (CG), the average (n = 6) LVEF and LVES of the model group (MG) reduced from 76.4 to 51.6%, and 48.2 to 31.5%, respectively (Figures 3A,B). Although the changes in LVEF and LVES between the controls and models were not as significant as those observed in patients with newly diagnosed DCM and heart failure (Cho et al., 2018), the alterations in LVEF and LVES together with the changes in the cardiac index (HWI) and left ventricular mass index (LVWI) between the controls and the models (Figures 3C,D), demonstrated that the models had developed pseudo-cardiomyopathy, termed as isoproterenol-induced cardiomyopathy (ISO-iCM) (Zhu et al., 2020).

Next, we evaluate the pharmacological effects of Descurainia sophia seeds (DS) and the combination of DS with Astragalus mongholicus (AM), astragaloside IV (AS4), calycosin-7-glucoside (C7G), and Astragalus polysaccharides (APS) on ISO-iCM in rats, based on the effect of various treatments on LVEF, LVFS, LVWI, and HWI levels of models. We found that AM and C7G slightly improved the pharmacological efficacy of DS, and AS4 significantly promoted the pharmacological effect of DS, whereas PLS showed little benefit for the pharmacological efficiency of DS on ISO-iCM (Figures 3A–D).

To evaluate further pharmacological efficiency of various combinations of DS with AM and the three active components of AM, we performed histopathological assays on the left ventricular myocardial tissues. The H&E staining results (Figures 3G,H) indicated that compared to the controls, the myocardial cells in the heart of models were significantly enlarged and hypertrophic and disorderly arranged accompanied with increased intercellular substances. Moreover, the inflammatory cell infiltration in the heart of the model was obvious. After treatment with DS or the combinations, these pathological phenotypes were diminished to a different extent (Figure 3I–M). Notably, the

| Compound no. | Accepted description | Retention time/min | m/z | Adducts | Formula | Abundance | Fold changea |
|--------------|----------------------|-------------------|-----|---------|---------|-----------|-------------|
| DS-31        | Convalloside         | 11.28             | 735.3238 | M + Na  | C16H22O15 | 81129     | 28.1        |
| DS-32        | Mirificin            | 6.86              | 547.1655 | M-H    | C14H16O5 | 78320     | 2798.7      |
| DS-33        | Bis [[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]malonate] | 7.48 | 427.1103 | M-H    | C12H16O6 | 70481 | 1752.4 |
| DS-34        | 4-Hydroxy-3-methyl-6-(trifluoromethyl)-4,5,6,7-tetrahydro-1-benzofuran-2-carboxylic acid | 7.66 | 287.0493 | M + Na  | C11H12F3O2 | 68140 | 144.5 |
| DS-35        | N-Hydroxy-2-(4-phenyl-1,3-thiazol-2-yl)ethanamidine | 8.63 | 232.0549 | M-H    | C11H11N3OS | 66872 | 2358.5 |
| DS-36        | (6E)-4-Hydroxy-1,7-diphenyl-6-hepten-3-one | 9.95 | 303.1333 | M + Na  | C12H10O4 | 59840 | 43.1 |
| DS-37        | 5-(2-(Ethylsulfanyl)phenyl)-3-methyl-5-oxopenta-3-enic acid | 8.58 | 265.0878 | M-H    | C11H12O3S | 48253 | 12299.5 |
| DS-38        | (3Z)-2,10-Diaminono-4-(phosphononomethyl)-3-decenolic acid | 8.63 | 329.1039 | M + Cl  | C11H16N2O3P | 46056 | 214.8 |
| DS-39        | 1,2-O-Cyclohexylidene-a-D-glucorafuranose | 8.58 | 295.0971 | M + Cl  | C11H16O3 | 46002 | Infinity |
| DS-40        | Benzoic acid 3-[(acetoxylsulfonyl)methyl]-4-(1,3-benzoaxoldio-5-yl)-1-hydroxy-L-proplylglycinate | 6.65 | 467.1278 | M-H2O-H | C14H21O5N3 | 42389 | 2324.0 |
| DS-41        | GDC-0152            | 6.60              | 479.2119 | M-H2O-H | C11H15N3O4 | 42040 | 172.2 |
| DS-42        | Sakuranin           | 10.74             | 471.1286 | M + Na  | C12H16O3 | 36290 | 38.4 |
| DS-43        | Aklavetone          | 8.58              | 411.1090 | M + H   | C16H20O5S | 19893 | 25.9 |
| DS-44        | 1-[4-[[4-([(1R)-1-[[6S,7S)-2-Amino-7-methyl-4-oxo-1,4,5,6,7,8-hexahydro-6-pteridinyl]ethyl]amino)phenyl]-1-deoxy-5-O-(5-O-[[1S]-1,3-dicarboxypropoxy][hydroxy]phosphoryl)-alpha-D-ribofuranosyl]-D-ribitol | 8.81 | 799.2547 | M + Na  | C20H22N3O6P | 11051 | 33.2 |
| DS-45        | Neohesperidin dihydrochalcone | 8.45 | 635.1893 | M + Na  | C20H24O3 | 7239 | 42.8 |
| DS-46        | N-[[9H-Fluoren-9-yloxy]carbonyl]-N-methyl-1-[[2-methyl-2-propanyl]oxy]carbonyl]-l-histidine | 9.56 | 530.1665 | M + K   | C22H24O3N3 | 6166 | 51.8 |

aFold change = (abundance)DS/(abundance)AM

TABLE 1 (Continued) Components identified in Descurainia sophia seed decoction.
combined uses of DS with AS4 or C7G again resulted in further reduction in the severity of hypertrophy of myocardial cells and the content of intercellular substances in the hearts, compared with that treated with DS alone (Figures 3I, K, L), implying better pharmacological benefits on the heart injury in the model rats. However, the combination of DS with APS did not produce an improvement in the pharmacological efficiency of DS to ISO-iCM (Figures 3M).

We also performed Masson’s staining on the heart tissues of all groups (Figures 3N–P), where collagen fibers were stained in blue and myocardial cells in dark red. Based on Masson’s staining, the average cardiac collagen volume fractions (CVFs) of each group were calculated and depicted in Figure 3E. The results indicate that compared to the controls, the CVF value of model rats significantly increased (p < 0.01) but decreased to a large content after treatments, though the treatments did not reverse completely the CVF level of models. Again, we found that

TABLE 2 Components identified in Astragalus mongholicus decoction.

| Compound No. | Accepted description | Retention time/min | m/z | Adducts | Formula | Abundance | Fold change<sup>a</sup> |
|--------------|----------------------|--------------------|-----|---------|---------|-----------|-----------------------|
| AM-1         | Deslanoside          | 11.90              | 941.4749 | M-H     | C_{47}H_{74}O_{19} | 987131 | 270.0 |
| AM-2         | 2′-Methyl-1H,1′H,2.5′-benzimidazole | 9.20      | 283.0763 | M + Cl  | C_{9}H_{11}N_{4} | 973789 | 1673.7 |
| AM-3         | (1R,23R):14,17,20-Trihydroxy-14,20-dioxido-8,26-dioxo-9,13,15,19,21,25-hexaaza-14lambda:5−,20lambda:5− diphosphatriliacontane-11,23-diyldioctanoate | 13.26  | 885.4538 | M-H_{2}O-H | C_{67}H_{90}O_{32} | 948470 | 385.7 |
| AM-4         | 9,10-Dihydrobenzo [e]acephenanthrylene-5,9,10-triol | 8.94  | 283.0764 | M-H_{2}O-H | C_{30}H_{42}O_{11} | 890204 | 304.5 |
| AM-5         | 8′-Azaadenosine      | 9.95              | 267.0823 | M-H     | C_{16}H_{15}NO | 857889 | 458.3 |
| AM-6         | Decursinol           | 10.66             | 269.0800 | M + Na  | C_{8}H_{15}O_{4} | 829194 | 37.0 |
| AM-7         | Secalcalcit         | 13.08             | 437.3415 | M + H   | C_{33}H_{43}O_{3} | 723031 | 43.9 |
| AM-8         | (2E)-3-(2-(3-Ethylphenoxy)-5-fluorophenyl)acrylic acid | 11.67  | 267.0823 | M-H_{2}O-H | C_{30}H_{42}O_{12} | 690119 | 43.6 |
| AM-9         | 8′-apo-beta-carotene | 13.08             | 419.3309 | M + H   | C_{36}H_{42}O_{6} | 630918 | 94.6 |
| AM-10        | 2-Amonium-5-(1-carboxy-2-[(1Z)-N-hydroxy-2-phenylethanimidoyl]sulfanyl[ethyl]amine)-5-oxopentanooate | 2.64  | 382.1102 | M-H   | C_{16}H_{21}N_{3}O_{6}S | 594536 | 142.8 |
| AM-11        | 2-Pheny1-7-quinoxinecarbaldehyde | 8.94  | 268.0536 | M + Cl  | C_{16}H_{15}NO | 541619 | Infinity |
| AM-12        | OLMESARTAN LACTONE  | 10.61             | 463.1659 | M + Cl  | C_{24}H_{24}N_{6}O_{2} | 430921 | 123.8 |
| AM-13        | (6S,9aS)-N-Benzyl-6-(4-hydroxybenzyl)-2,9-dimethyl-4,7-dioxo-8-(8-quinolinylmethyl)hexahydro-2H-pyrazino [2,1-c][1,2,4]triazine-1(6H)-carboxamide | 9.02  | 577.2606 | M-H | C_{27}H_{42}O_{4} | 306730 | 244.4 |
| AM-14        | 3-Hydroxylup-18-en-21-one | 12.77            | 423.3613 | M + H   | C_{30}H_{42}O_{2} | 292174 | 55.0 |
| AM-15        | Dicyclohexyl[5-(2,6-dimethoxybenzyl)benzyl]phosphine | 7.40  | 461.2959 | M + Na  | C_{28}H_{36}O_{2}P | 110198 | 52.7 |
| AM-16        | Ganoderal A          | 12.11             | 437.3410 | M + H   | C_{33}H_{44}O_{5} | 107669 | 107.5 |
| AM-17        | Astragaloside III    | 12.95             | 807.4493 | M + Na  | C_{47}H_{52}O_{14} | 95644 | 30.2 |
| AM-18        | Astragaloside II     | 13.08             | 884.4615 | M + Na  | C_{47}H_{50}O_{15} | 92457 | 43.1 |
| AM-19        | Metoprolol succinate | 13.83             | 653.4049 | M + H   | C_{24}H_{43}N_{10} | 83919 | 1307.8 |
| AM-20        | Soyasaponin I       | 12.77             | 965.5083 | M + Na  | C_{42}H_{56}O_{18} | 75689 | 152.5 |
| AM-21        | N-2-[(8-Fluoro-6-[(2-methyl-2-propanyl)sulfonyl]-5-pyridinyl]-3-pyridinyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]carbamoyl]-N,N-dimethylglycinamide | 2.02  | 473.1553 | M-H_{2}O-H | C_{30}H_{57}N_{4}O_{2}S | 75544 | 28.4 |
| AM-22        | (5R,2,4-Dideoxy-1-C-[(2S,3R,4S)-3-hydroxy-4-[(2R,5S,6S,8R,10S,11R,12S,14E)-10-hydroxy-3,15-dimethoxy-2,11,13,14-tetramethyl-16-oxoacyclohexadeca-4,6,12,14-tetra-2,7,12-pentanyl]-5-isopropyl-4-methyl-alpha-D-threo-pentopyranosanoyl)pentapyranose | 13.26  | 645.3974 | M + Na  | C_{30}H_{45}O_{14} | 49716 | 70.1 |
| AM-23        | Astragaloside IV     | 13.13             | 807.4506 | M + Na  | C_{42}H_{57}O_{18} | 42693 | 34.4 |

<sup>a</sup>Fold change = (abundance)AM/(abundance)DS
FIGURE 2
Chemical structure of (A) quercetin-7-O-β-D-glucopyranosyl (1→6)-β-D-glucopyranoside, (B) quercetin, and (C) astragaloside IV.

FIGURE 3
Phenotypic and pathological characterization (A–F), left ventricular ejection fraction (LVEF, (A)), left ventricular fraction shortening (LVFS, (B)), heart index (HWI, (C)), left ventricular mass index (LVWI, (D)), collagen volume fraction (CVF, (E)) of myocardial cells, and plasma CK levels (F) of rats of the control (CG), model (MG), and treated groups with Descurainia sophia seed decoction alone (DS), and Descurainia sophia seeds plus Astragalus mongholicus decoction (DSAM), Descurainia sophia seeds decoction plus astragaloside IV (DSAS4), calycosin-7-glucoside (DSC7G), or Astragalus polysaccharides (DSAPS). The results of LVEF, LVFS, HWI, LVWI, CVF, and CK were measured by randomly selecting six rats (n = 6) from each group and are represented as mean ± SD. *p < 0.05 and **p < 0.01, ***p < 0.001 and ****p < 0.0001, represent statistical significance and high significance, respectively. (G–M) H&E (400×) and (N–T) Masson’s (200×) trichrome staining of heart tissues of all groups. For Masson’s staining, collagen fibers were stained in blue, and myocardial cell in dark red.
the treatment with DS combined with AS4 exhibited the highest effectiveness to reverse the CVF level (Figure 3R). Meanwhile, this combined treatment also reverses the plasma myocardial enzyme creatine kinase (CK) level of model rats to close to that of controls (Figure 3F). Given the increased expression of CK in plasma is an important diagnostic marker of myocardial ischemia (Holmvang et al., 1998), these results indicate that the treatment with DS and AS4 significantly alleviated myocardial cell necrosis, resulting from myocardial ischemia in rats with ISO-iCM.

Identification of differential expressed proteins

After phenotypic characterization and physiological evaluation of rats with ISO-iCM before and after various treatments, we performed mass spectrometry (MS)-based quantitative proteomics analysis on the heart of rats to investigate the pharmacological efficiency of various treatments at a molecular level. The protein extraction from heart tissues and the subsequent MS/MS analysis were carried out in three independent replicates. In total, peptide matching spectrum maps allowed us to identify 55,307 peptides and 10,418 peptide groups, corresponding to 1,858 proteins. Of these 902 proteins were detected in three parallel sets, and 213 proteins were considered statistically reliable with a p-value <0.05 (Figures 4A,B, Supplementary Table S5). Among the 213 proteins were 24 proteins upregulated by more than 1.5-fold and 1 protein downregulated by more than 1.5-fold in the model rats compared to the counterparts in the controls (Figure 4C).

Among the 25 differentially expressed proteins (DEPs) (Figure 4C), the most significantly upregulated protein in the rats with ISO-iCM was natriuretic peptides A (NPPA), of which the fold-change (FC), designated as the abundance ratio of an upregulated protein in MG vs. CG, but as negative reciprocal of abundance ratio of a downregulated protein in MG vs CG, was 11.8. All 25 DEPs were grouped by the Proteome Discoverer (PD) software into extracellular matrix proteins, myosin family, intermediated filament family, actin or actin filament binding proteins, metabolism-related proteins, immune-related proteins, and calcium sensors (Table 3). It is worth to point out that the members of the myosin family, intermediated filaments, and actin filament binding proteins are all related to sarcomere modulation of the heart (Anderson et al., 2018; Daniels et al., 2021; Lehman et al., 2022). More importantly, the myosin proteins MYL4, MYH6, and MYH7, which work with actin to

FIGURE 4
Differential expression proteomics of the heart of rats in the control group (CG) and ISO-iCM model group (MG). (A) Number of proteins identified in three parallel replicates. (B) Volcanic map of the proteins identified in both the control (CG) and model (MG) groups with various abundance ratios (ARs) and p-values. Orange point refers to a protein with a log2AR (MG vs. CG) of ≥0.59 or ≤−0.59 and a p-value of <0.05; blue to a protein with a log2AR of >−0.59 or <0.59 and a p-value of <0.05, gray to a protein with a p-value of >0.05. (C) Fold changes (FCs) of 25 differentially expressed proteins in the heart of the model group (MG) compared to those in the control group (CG). The insert is the Western blotting bands of the representatives of DEPs, NPPA, TMP1, and TMP2 in the heart of rats in CG, MG, and the treated group with Descurainia sophia seeds decoction plus astragaloside IV (DSAS4). GAPDH was used as an internal reference.
regulate the myocardial contraction (Daniels et al., 2021), were remarkably upregulated in the heart of the rats with ISO-iCM. This with the most significant upregulation of the commonly accepted biomarker NPPA to cardiomyopathy confirms the successful establishment of the ISO-iCM models at the molecular level.

Next, we performed MS quantitative proteomics analysis on the heart of the five treated groups. As shown in Figure 5A and the Supplementary Table S5, subjected to the treatment with DS alone, the expression of the most 25 DEPs were reversed to a different extent except for COL1A2, COL1A1, BDH1, MYH7, and MYH6, among which COL1A1, COL1A2, MYH6, and MYH7, especially MYH7, were further regulated, but d-β-hydroxybutyrate dehydrogenase (BDH1) in mitochondrion was downregulated, compared to the models. In TCM practices, DS is often used in combination with AM to treat cardiac diseases (Yu et al., 2021). However, our proteomic data showed that this combination did not pronouncedly improve the pharmacological effectiveness, though AM appeared to reverse the expression of BDH1, which was downregulated by DS, to the control level (Figure 5A). This may be contributable to the upregulation of NPPA and MYL by AM, compared to the DS treated group (Figure 5A). Interestingly, the major active component of AM, AS4 not only reversed the further expression of NPPA and myosin such as MYH6 and MYL closer to the control level but also reversed the expression of MYH7 and BDH1, which were upregulated and downregulated, respectively, by DS (Figure 5A). We also noticed that APS significantly upregulated MYL and NPPA, which were the most and the second upregulated proteins in the heart of model rats with ISO-iCM, compared with the DS-treated group. These results indicate that the upregulation of NPPA and MYL, resulting from AM may be attributed to its active component APS (Figure 5A).

To verify the expression of the DEPs identified by quantitative proteomics analysis, we selected three NPPA, TPM1, and TPM2, the molecular weights of which locate at the low, medium, and high levels, respectively, to perform the traditional Western blot assays. As shown in the inset of Figure 4C, the results confirmed that compared to the control group (CG), NPPA, TPM1, and TPM2 were all significantly upregulated, and the combination of DS with AS4 remarkably reversed the expression of the three proteins.

### Table 3 Differentially expressed proteins in the heart of rats with ISO-iCM.

| Category             | Accession | Gene symbol | Protein name (abbreviation) |
|----------------------|-----------|-------------|-----------------------------|
| Extracellular matrix protein | O08590    | Aoc3        | Membrane primary amine oxidase (AOC3) |
|                      | Q07936-1  | Anxa2       | Annexin A2 (ANXA2)          |
|                      | P02466    | Col1a2      | Collagen alpha-2(I) chain (COL1A2) |
|                      | P02454    | Col1a1      | Collagen alpha-1(I) chain (COL1A1) |
|                      | P05371    | Clu         | Clusterin (CLU)             |
|                      | P51886    | Lum         | Lumican (LUM)               |
|                      | Q9EQP5    | Prelp       | Prolargin (PRELP)           |
|                      | P14925-1  | Pum         | Peptidyl-glycine alpha-amidating monoxygenase (PAM) |
| Myosin family protein | Q63862-1  | Myh11       | Myosin-11 (MYH11)           |
|                      | P13832    | Myh12a      | Myosin regulatory light chain RLC-A (MYL12A) |
|                      | Q64119-2  | Myhl       | Myosin light polypeptide 6 (MYL6L) |
|                      | P02564    | Myh7        | Myosin-7 (MYH7)             |
|                      | P02563    | Myh6        | Myosin-6 (MYH6)             |
|                      | P17209    | Myf4        | Myosin light chain 4 (MYL4) |
| Intermediated filaments | P31000    | Vim         | Vimentin (VIM)              |
|                      | P21807    | Pph         | Peripharin (PRPH)           |
| Actin filament binding protein | P31232    | Tagln       | Transglisin (TAGLN)         |
|                      | P04692-2  | Tpm1        | Isoform 2 of tropomyosin alpha-1 chain (TPM1) |
|                      | P58775-2  | Tpm2        | Isoform 2 of tropomyosin beta chain (TPM2) |
| Metabolism-related protein | P29147    | Bdhl        | D-beta-hydroxybutyrate dehydrogenase (BDH1) |
|                      | P16303    | Cesi1d      | Carboxylesterase 1D (CES1D) |
|                      | P01161    | Nppa        | Natriuretic peptides A (NPPA) |
| Immunity-related protein | Q811A2    | Bst2        | Bone marrow stromal antigen 2 (BST2) |
|                      | P01835    | Igkc        | Ig kappa chain C (LOC500180) |
| Calcium sensor       | P05964    | St100a6     | Protein S100-A6 (S100A6)    |
We performed principal component analysis (PCA) based on the protein profiling, including all 213 proteins detected in the heart of all six groups. The results indicated that among the five treated groups, the combination of DS with AS4 (DSAS4) made the treated group closer to the control group in the PC1 direction (Figure 5B), suggesting the highest pharmacological effect of this combination on ISO-iCM in rats. This is most likely contributable to the reversion of expression of NPPA, MYL4, and PAM, which contributes the most to PC loading in the positive direction (Figures 5A–C). In contrast, the treatment with DS and APS (DSAPS) made the treated group further away from the control one in the PC1 positive direction (Figure 5B) because this treatment further upregulated the expression of NPPA, MYL4, and PAM (Figure 5C). In other words, NPPA, MYL4, and PAM may serve as potential predictors and biomarkers for the diagnosis and prognosis of cardiomyopathy.

**Bioinformatics analysis**

To further dissect the functions and roles of the 25 DEPs (Table 3) in the heart of rats with ISO-iCM, we next performed bioinformatics analysis on these proteins. First, the 25 DEPs were uploaded into STRING 11.0 for protein–protein interaction (PPI) analysis. As shown in Figure 6A, the PPI network of the 25 DEPs consists of 25 nodes (genes/proteins) and 54 edges (interactions), which indicates that 18 of the 25 DEPs interact with each other and that the interactions could be grouped at four levels based on the edge confidence scores. One interaction group with high confidence level covers four extracellular matrix (ECM) proteins, PRELP, LUM, COL1A1, and COL1A2, of which the primary function is cell connecting. Another interaction group with a high confidence level contains VIM, MYL4, MYH7, MYH11, MYH6, MYL12a, TAGLN, TPM2, and...
TPM1, which are all located in the cytoplasm and mainly regulate the structure and function of the sarcomere (Toepfer et al., 2020). Interestingly, being a member of type III intermediate filament proteins VIM directly interacts with the members of both the myosin family and ECM family. This suggests that VIM plays an essential role in ISO-iCM via involvement in the development of cytoskeleton and sarcomere, which are modulated by ECM proteins and myosin motor, respectively, associating with actin and/or actin-filament binding proteins such as TAGLN, TPM2, and TPM1.

Natriuretic peptides A (NPPA) is an energy metabolism-related protein and mediates cardio-renal homeostasis by binding to and stimulating NPR1 to produce cGMP (Ogawa et al., 2004). As shown in Figure 6A, NPPA directly interacts not only with the myosin proteins such as MYH6 and MYH7, of which both are molecular motors of the sarcomere (Toepfer et al., 2020; Daniels et al., 2021) but also with actin cross-linking/gelling protein TAGLN (Huang et al., 2018b), actin filament binding proteins TPM1/2 (Rani et al., 2015), and the intermediate filament protein VIM (Hol and Capetanaki, 2017), which are all involved in the binding of myosin to actin, modulating the myosin motor (Anderson et al., 2018; Lehman et al., 2022). In addition, NPPA directly interacts with ECM protein COL1A1 weakly. These implicate that NPPA plays a crucial role in the development of ISO-iCM by participating regulation of sarcomere structure and function.

As mentioned earlier, we induced cardiomyopathy in rats by isoproterenol, which is a non-specific β-AR agonist and can increase inotropy, chronotropy, and systemic vasodilation (Verma et al., 2012). The activation of the signal transducer and activator of transcription 3 (STAT3) can rapidly upregulate the expression of some cellular proteins, including NPPA and MYH7 (Figure 7), which were significantly upregulated in rats with ISO-iCM (vide supra) and in the patients with DCM (Chan et al., 2020; Toepfer et al., 2020). On the other hand, STAT3 activates the transcription regulator GATA4 (Snyder et al., 2010; Wang et al., 2018), thereby upregulating the expression of NPPA, MYH7, and MYH6 (Figure 7), which interacted with each other to regulate the structure and function of the sarcomere, resulting in heart failure and arrhythmias (Toepfer et al., 2020).

It is worth pointing out that similar to VIM and NPPA, the calcium sensor and modulator S100A6 is also upregulated in the heart of rats with ISO-iCM. Given that S100A6 is involved in the regulation of cytoskeleton and sarcomere structures by interacting with ANXA2, TAGLN, and MYL12a, which are all upregulated in the model rats, the elevated level of S100A6 may contribute to the disorder in cytoskeleton and cardiomyocyte motility via modulating the homeostasis of calcium ions (Breen and Tang, 2003; Nowotny et al., 2003).

Being a member of the myosin family and molecular motors of the sarcomere, Myosin 11 (MYH11) is a protein complex contributing to cell contraction by hydrolysis of ATP (Zhu et al., 2006). The mutation of the Myh11 gene may cause familial thoracic aortic aneurysm and dissection heart, in which the aortic was enlarged near the heart (El-Hamamsy and Yacoub, 2009). There have been so far few reports on the relationship of MYL12a with heart-related diseases, but Park et al. (2011) found that this protein could influence cell morphology and dynamics by sustaining the stability of the Myosin 11. In Myl12a knockout cells, the MYH9, MYH10, and MYH6 expressions were significantly reduced. Taking together, our work suggests that

![FIGURE 6](image-url)
MYH11 and MYH12a are also implicated in the development of ISO-iCM in rats in addition to other members, MYL4, MYH6/7, and MYL6L, of the myosin family.

Both PRPH and VIM belong to the type III intermediate filament family. PRPH is primarily expressed in peripheral neurons. The expression of Prph is upregulated during neuron development or regeneration when axons were injured (Hol and Capetanaki, 2017). With regard to this, the upregulation of PRPH in rats with ISO-iCM may suggest damage to the nervous system of the heart. VIM is mainly expressed in undifferentiated mesenchymal origin cells and regulates the functions of the lysosome, Golgi complex, and mitochondria organelles. Moreover, VIM can also influence the transportation of the integrins to the plasma membrane, and may then impact cell-extracellular matrix adhesion (Hol and Capetanaki, 2017). Taking this into account, the intermediate filament family proteins PRPH and VIM may be involved in the development of ISO-iCM in rats via damaging heart nerves and regulating cytoskeleton and myofibril structure.

Transgelin (TAGLN) is an actin filament binding protein and is also named smooth muscle protein 22-α (SM22-α). It was reported to be associated with tumorigenesis (Yu et al., 2013). Studies on patients with pulmonary arterial hypertension (PAH) in congenital heart disease (CHD) showed that TAGLN overexpression may promote the proliferation, migration, and cytoskeleton strengthening of pulmonary arterial smooth muscle cells (PASMCs) (Huang et al., 2018a). The upregulation of TAGLN in the heart of rats with ISO-iCM implicates its participation in cardiomyopathy by functioning as smooth muscle protein.

The membrane primary amine oxidase (AOC3) is an extracellular matrix protein. Although there is no evidence for direct association of AOC3 with heart failure, this protein has been identified as a new marker of myofibroblasts (Hsia et al., 2016). Hence, the protein is likely to be involved in the process of cardiomyocyte fibrosis and has a close relationship with ISO-iCM.

Two immune-related proteins, the Ig kappa chain C region (LOC500180) and BST2 were unraveled to be significantly upregulated and downregulated, respectively, in the heart of rats with ISO-iCM. A clinical study suggested that combined free light chains (cFLCs), which include both kappa and lambda FLCs, could be a marker of heart failure prognosis (Jackson et al., 2015). However, another report argued that a more mechanistic understanding of heart failure pathophysiology is needed to support the conclusion (Januzzi and Mann, 2015). Our results herein verified that Ig kappa chain C may play an important role in cardiomyopathy, perhaps via involvement in the...
inflammatory pathway (Kang et al., 2009). BST2 is the only protein that was downregulated in rats with ISO-iCM. It is an antiviral antigen implicated in the regulation of viral infection (Evans et al., 2010). Despite its antiviral functions, BST2 may be involved in some disease manifestations, for example, cancer and autoimmune diseases (Mahauad-Fernandez and Okeoma, 2016). Recently, the research found that circulating healing (CH) cells expressing BST2 are functionally activated by the injury-regulated systemic factor hepatocyte growth factor-activator (HGFA), which could participate in tissue repair (Lo Sicco et al., 2018). With regard to this, our finding that BST2 was downregulated in rats with ISO-iCM implies myocardial inflammatory damage in the rats.

The gene ontology (GO) enrichment showed that the most associated Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and biological process (BP) of the 25 DEPs are cardiac muscle contraction and muscle system process, respectively (Figure 6B). Since the most of the 25 DEPs, including eight extracellular matrix proteins and six myosin family proteins, and five actin-binding proteins, are involved in the cytoskeleton and myofibril structure and function, the disorders in cardiac muscle contraction, in particular structure and function of sarcomeric myosin motor, is most likely the main pathogenic elements of ISO-iCM in rats, similar to DCM and HCM in human.

The functional enrichment by STRING added 100 proteins (nodes) and 1,437 interactions (edges) to the initial 25 DEPs by matching the best interactor criteria (Supplementary Figure S6A). Notably, GO analysis annotated the most associated KEGG pathway and the biological process (GOBP) of the 125 proteins to be focal adhesion and muscle system process (Supplementary Figure S6B), again indicating that abnormality in structures of cytoskeleton and sarcomere are the characteristic phenotypes of ISO-iCM in rats.

Next, we applied the Ingenuity Pathway Analysis (IPA) program to enrich the core signaling pathways, which the 25 DEPs are associated with. The top 20 core signaling pathways of which the 25 DEPs are most associated with are depicted in Supplementary Figure S7. We can see that the myosins, for example, MYH6 and MYH7, and tropomyosins (TPM1 and TPM2) are deeply implicated in the dilated cardiomyopathy signaling pathway (Supplementary Figure S8) and the calcium signaling pathway (Supplementary Figure S9), of which both play a crucial role in the contractility of cardiac cell and the remodeling of the myocardium (Figure 8).
Discussion

The occurrence and development of heart failure are closely related to the disorder of water and electrolyte metabolism (Chobanian et al., 1957), which are mainly modulated by natriuretic peptides A (NPPA) and GMP signaling (Moro and Lafontain, 2013; Song et al., 2015). In this work, we used isoproterenol to induce cardiomyopathy in rats. Our results indicated that isoproterenol is bound to β2-adrenergic receptor, and indeed upregulated NPPA expression by activating STA3 and GATA4 in the heart of rats. Meanwhile, the activation of STAT3 and GATA4 also promoted remarkably the expression of myosins MYH6, MYH7, MYH11, and MYL4, and tropomyosins TPM1 and TPM2. The myocardial contraction requires two proteins, myosin, and actin (Daniels et al., 2021). Sarcomeric myosin is the molecular engine of the heart, which converts the chemical energy of ATP into movement and regulates force production for contractility of the whole heart. Myosin acts as a molecular accelerator or brake depending on whether and how it binds to actin. Actin is controlled by fluctuating calcium levels, which regulate a molecular clutch shielding actin via the troponin complex (TPM1 and TPM2) from myosin in a low diastolic Ca2+ level and exposing actin at a high systolic Ca2+ level (Daniels et al., 2021) to myosin binding, thereby activating myosin-ATPase activity to power heart movement. Therefore, any changes in ATP consumption and force production caused by genetic mutations on myosin and/or abnormal activation/suppression of myosin motor could lead to cardiac diseases, for example, hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). With regard to this, several small molecule inhibitors and activators of myosin have been developed for treating inherited cardiomyopathies with genetic variants in myosin and entered different phases of clinic trails (Lehman et al., 2022). The drug candidates, for example, mavacamten, were demonstrated to have a spatially distinct effect in the sarcomere and are thought to be root-targeting therapeutics without harmfulness to other organs (Lehman et al., 2022).

Our quantitative proteomics data demonstrated that apart from about 12-fold increase in the NPPA level, the expression levels of myosin family proteins, MYL4, MYH6, MYH7, MYL12A, MYL6L, and MYH11, and actin filament binding proteins TAGLN, TPM1, and TPM2, were all elevated in the heart of the model rats with ISO-iCM. This remarkably indicates the upregulation of myosin-ATPase activity. Taking the increase in the expression of calcium sensor S100A6 into account, the model rats appeared to have similar characteristics to the inherited HCM, in which the genetic variants in sarcomeric myosin and myofilament increase the proportion of active myosin, that is, more accelerator and less brake, leading to diastolic dysfunction and hypercontractility (Daniels et al., 2021). Also, thanks to the precise MS quantification of proteins, we demonstrated that DS significantly reversed the expression of the myosin family proteins and actin filament binding proteins, except for MYH6 and MYH7, showing a good pharmacological effect on ISO-iCM in rats. More importantly, our study revealed that the major active component AS4 in AM remarkably improved the pharmacological efficiency of DS on ISO-iCM in rats by complementarily reversing the expression of MYH6 and MYH7, and further downregulating NPPA, MYK4, and PAM. These results strongly suggest that the combination of DS with AS4 exerted pharmacological benefits on ISO-iCM in rats by synergistically modulating the myosin motor. Another active component calycosin-7-glucoside (C7G) was also shown to improve the pharmacological efficacy of DS on ISO-iCM. However, the improvement was less than AS4, most likely due to the weaker ability of C7G to downregulate NPPA, MYL4, and PAM.

As mentioned earlier, AM is often used in combination with DS. However, in the present work, we did not find that the combination of DS and AM produced a pronouncedly higher pharmacological potential for ISO-iCM in rats than the use of DS alone. We have also investigated the pharmacological efficiency of AM used alone and found that the pharmacological effect of AM alone on ISO-iCM in rats was poor (data now showed). To sort out why the combination of DS and AM could not provide better pharmacological benefits on ISO-iCM, we further studied the effect of Astragalus polysaccharides (APS) on the pharmacological efficiency of DS. Surprisingly, we found that APS upregulated NPPA, MYL4, and PAM, which are the most contributors to the development of ISO-iCM in rats, thereby reducing the pharmacological efficiency of DS on ISO-iCM. This suggests that it is the presence of APS in AM that reduced the pharmacological effect of DS combined with AM on ISO-iCM in rats. These findings imply that the combination of TCMs is highly necessary, but that the simple combination may not produce expected outcomes.

On the other hand, our quantitative proteomics results showed that DS decoction significantly upregulated the expression of MYH7, which as mentioned earlier plays a vital role in development of cardiomyopathy, and downregulated the expression of BDH1, which acts as an actin filament binding protein and is involved in cardiac diseases (Brahma et al., 2020). However, we herein did not identify which components in DS caused the differential expression of these two proteins. To address this issue, it is necessary to perform the proteomics analysis after treating the ISO-iCM model rats with purified active components, for example, quercetin and kaempferol, from DS. This work will be undertaken in the near future in our laboratory.
Conclusion

In this work, with the use of quantitative mass spectrometric proteomics analysis, we revealed for the first time that the classic traditional Chinese medicine, Descurainia sophia seeds (DS) relieved isoproterenol-induced cardiomyopathy (ISO-iCM) in rats by reversing the most of differentially expressed proteins (DEPs), including molecular motor MYL4 and the well-known biomarker NPPA of cardiomyopathy. Importantly, we demonstrated that the combined use of DS with Astragalus mongholicus (AM) did not provide better pharmacological benefit to ISO-iCM, while astragaloside IV (AS4), a major active component in AM, significantly improved the pharmacological effect of DS on ISO-iCM via complementarily or further reversing myosins MYH6/7, and NPPA and MYL4. This suggests that DS and AS4 synergistically work on modulating the myosin motor in sarcomere to achieve better pharmacological benefit to cardiomyopathy. In contrast, the combination of DS with Astragalus polysaccharides (APS) from AM even reduced the pharmacological efficiency of DS to ISO-iCM in rats, most likely contributing to the less improvement of AM on the pharmacological efficiency of DS. This work highlights the power of mass spectrometric proteomics strategy combined with conventional pathological approaches for the development and modernization of TCM. Significantly, our findings provide novel insights to better understanding and improving the combination pharmacological principle of traditional Chinese medicine.

Data availability statement

The datasets of proteomics analysis presented in this study can be found in online Proteomics Identification Database at ebi.ac.uk/pride/ with a reference number of 1-20220509-37752.

Ethics statement

The animal study was reviewed and approved by Ethics Committee of Shandong University of Traditional Chinese Medicine.

References

Anderson, R. L., Trovedi, D. V., Sarkar, S. S., Henze, M., Ma, W. K., Gong, H., et al. (2018). Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc. Natl. Acad. Sci. U. S. A. 115 (35), E8143–E8152. doi:10.1073/pnas.1809540115

Brahma, M. K., Ha, C. M., Pepin, M. E., Miu, S., Sun, Z., Chatham, J. C., et al. (2020). Increased glucose availability attenuates myocardial ketone body utilization. J. Am. Heart Assoc. 9 (15), e013039. doi:10.1161/jaha.119.013039

Breen, E. C., and Tang, K. (2003). Calcyclin (S100A6) regulates pulmonary fibroblast proliferation, morphology, and cytoskeletal organization in vitro. J. Cell. Biochem. 88 (4), 848–854. doi:10.1002/jcb.10398

Chan, M. Y., Efthymios, M., Tan, S. H., Pickering, J. W., Troughton, R., Pemberton, C., et al. (2020). Prioritizing candidates of post-myocardial infarction heart failure using plasma proteomics and single-cell transcriptomics. Circulation 142 (15), 1408-1421. doi:10.1161/circulationaha.119.045158

Author contributions

FWand SW conceived and supervised the project. SW, FW, QL, and QC obtained the fundings. XL, QL, JH, SL, JL, YZ, and YZ performed mass spectrometry and data analysis. QC, XJ, WY, and TW conducted animal experiments and pathological assays. FW, SL, XL, FZ, and QC wrote and revised the manuscript. All authors approved the final version of the manuscript.

Funding

This work was partially supported by the National Natural Science Foundation of China (Nos. 81673852 (SW), 82104554 (QC)), Beijing Municipal Natural Science Foundation (No. 7182190 (QL)), Natural Science Foundation of Shandong Province (ZR2021MH313 (QC)), Shandong Province TCM Science and Technology Development Plan Project (NO.2019-0048, (QC)) and the National Key Research and Development Program of China (No. 2013CB531805 (FW)).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.939483/full#supplementary-material
Astragalosides have been investigated as a potential target in the reversibility of pulmonary arterial hypertension (PAH) and heart failure.

### Evaluation of the Effect of Shengxian Decoction on Doxorubicin-Induced Chronic Heart Failure in a Mouse Model

Shengxian Decoction (SXD), a traditional Chinese herbal formula, has been evaluated for its cardioprotective effects in a mouse model of doxorubicin-induced chronic heart failure. The study used a mouse model of doxorubicin-induced chronic heart failure to assess the efficacy of SXD.

1. **Methods**
   - **Animal Model:** Male C57BL/6J mice were used for the study.
   - **Dose and Administration:** Mice were administrated with doxorubicin (DOX) and SXD in a randomized manner.
   - **Assessment:** Echocardiographic and histological assessments were performed to evaluate the cardiotoxicity.

2. **Results**
   - SXD significantly reduced the progression of doxorubicin-induced cardiomyopathy.
   - The cardioprotective effect of SXD was associated with improved cardiac function and reduced cardiac hypertrophy.

3. **Conclusion**
   - SXD has promising cardioprotective effects in a mouse model of doxorubicin-induced chronic heart failure.

### Protective Effect of Astragaloside IV on Cardiac Myocardium Injury

Astragaloside IV, a primary active component of Astragalus, has been studied for its protective effect on myocardial injury induced by isoproterenol in rats.

1. **Methods**
   - **Animal Model:** Male Sprague-Dawley rats were divided into control, isoproterenol, and Astragaloside IV-treated groups.
   - **Assessment:** Echocardiographic and histological assessments were performed to evaluate the cardiac function and injury.

2. **Results**
   - Astragaloside IV significantly reduced the cardiac injury induced by isoproterenol.
   - The protective effect was associated with improved cardiac function and reduced cardiac hypertrophy.

3. **Conclusion**
   - Astragaloside IV ameliorates isoproterenol-induced cardiac injury by modulating cardiac metabolism and improving cardiac function.

### Effects of Compatibility of Radix Astragali seu Hedysari and Semen Lepidii on the Control of Blood Pressure

Compatibility of Radix Astragali seu Hedysari and Semen Lepidii has been studied for its potential in controlling blood pressure.

1. **Methods**
   - **Animal Model:** Male Wistar rats were used for the study.
   - **Assessment:** Blood pressure and heart rate were recorded before and after treatment with the herbal combination.

2. **Results**
   - The herbal combination significantly reduced blood pressure and improved heart rate compared to the control group.

3. **Conclusion**
   - The herbal combination has potential in the treatment of hypertension.

### Protective Effect of Astragaloside IV on Cardiac Hypertrophy

Astragaloside IV, a component of Astragalus, has been studied for its protective effect on cardiac hypertrophy.

1. **Methods**
   - **Animal Model:** Male Sprague-Dawley rats were used for the study.
   - **Assessment:** Cardiac hypertrophy was assessed by echocardiography and histology.

2. **Results**
   - Astragaloside IV significantly reduced cardiac hypertrophy.
   - The protective effect was associated with reduced myocardial fibrosis and improved cardiac function.

3. **Conclusion**
   - Astragaloside IV has potential in the treatment of cardiac hypertrophy.

### Summary

These studies highlight the potential of Astragalus and its active components in the treatment of cardiac diseases, including PAH, heart failure, myocardial injury, and cardiac hypertrophy. Further research is needed to elucidate the mechanisms and develop effective therapeutic strategies.
isoproterenol-induced pathological remodeling in mice. *Redox Biol.* 27, 101212. doi:10.1016/j.redox.2019.101212

Shen, S., Sewanan, L. R., Jacoby, D. L., and Campbell, S. G. (2021). Danicamtiv enhances systolic function and frank-starling behavior at minimal diastolic cost in engineered human myocardium. *J. Am. Heart Assoc.* 10, e020860. doi:10.1161/JAHA.121.020860

Snyder, M., Huang, X. Y., and Zhang, J. J. (2010). Stat3 directly controls the expression of Thbx5, Nkx2.5, and GATA4 and is essential for cardiomyocyte differentiation of P19CLE6 cells. *J. Biol. Chem.* 285 (31), 23639–23646. doi:10.1074/jbc.M110.101083

Song, W., Wang, H., and Wu, Q. Y. (2015). Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). *Gene* 569 (1), 1–6. doi:10.1016/j.gene.2015.08.029

Stapel, B., Kohlbassa, M., Riecke-Hoch, M., Haghikia, A., Erschow, S., Knutti, J., et al. (2017). Low STAT3 expression sensitizes to toxic effects of beta-adrenergic receptor stimulation in peripartum cardiomyopathy. *Eur. Heart J.* 38 (5), 349–361. doi:10.1093/eurheartj/ehw086

Tan, Y. Q., Chen, H. W., and Li, J. (2020). Atrial fibrillation: IV. an effective drug for the treatment of cardiovascular diseases. Drug Dev. Res. 71, 3731–3746. doi:10.1002/ddr.247355

Teepeger, C. N., Garfinkel, A. C., Venturini, G., Wakimoto, H., Repetti, G., Alamo, L., et al. (2020). Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. *Circulation* 141 (10), 828–842. doi:10.1161/CIRCULATIONAHA.119.042339

Tripathi, R., Sullivan, R., Fan, T. M., Wang, D., Sun, Y., Reed, G. L., et al. (2017). Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy. *PloS One* 12 (12), e0189315. doi:10.1371/journal.pone.0189315

Verma, S. K., Krishnamurthy, P., Barefield, D., Singh, N., Gupta, R., Lamberts, E., et al. (2012). Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-kappa B. *Circulation* 126 (4), 418–429. doi:10.1161/CIRCULATIONAHA.112.112185

Wang, K. K., Ding, R. R., Ha, Y. P., Jia, Y. A., Liao, X. M., Wang, S. S., et al. (2018). Hypoxia-stressed cardiomyocytes promote early cardiac differentiation of cardiac stem cells through HIIF-1a/jagged1/Notch1 signaling. *Acta Pharmacol. Sin.* B 8 (5), 795–804. doi:10.1046/j.aps.2018.06.003

Wang, X. P., Li, W. L., Zhang, Y. W., Sun, Q. B., Cao, J., Tan, N. N., et al. (2022). Calycosin as a novel PI3K activator reduces inflammation and fibrosis in heart failure through AKT-IKK/STAT3/PGC-1α pathways. *Biomed. Pharmacother.* 141, 101212. doi:10.1016/j.biopha.2020.101212

Xie, W. J. X., Pang, Z., and Wang, S. (2015). Establishment and evaluation of the rat model of harmful fluid retention in the upper jiao. *World J. Integr. Traditional West. Med.* 10, 767–770.

Xu, C., Tang, F., Lu, M., Yang, J., Han, R., Met, M., et al. (2016). Astragaloside IV improves the isoproterenol-induced vascular dysfunction via attenuating eNOS uncoupling-mediated oxidative stress and inhibiting NF-kappaB pathways. *Int. Immunopharmac.* 33, 119–127. doi:10.1016/j.intimp.2016.02.009

Yamada, T., and Nomura, S. (2021). Recent findings related to cardiomyopathy and genetics. *Int. J. Mol. Sci.* 22 (22), 12522. doi:10.3390/ijms22212522

Yin, F., Li, P., Zheng, M., Chen, L., Xu, Q., Chen, K., et al. (2003). Interleukin-6 family of cytokines mediates isoproterenol-induced delayed STAT3 activation in mouse heart. *J. Biol. Chem.* 278 (23), 21070–21075. doi:10.1074/jbc.M211028200

Yu, B., Chen, X., Li, J., Qu, Y., Su, L., Peng, Y., et al. (2013). Stromal fibroblasts in the microenvironment of gastric carcinomas promote tumor metastasis via upregulating TAGLN expression. *BMC Cell Biol.* 14, 17. doi:10.1186/1471-2221-14-17

Yu, Y. D., Xiu, Y. P., Li, Y. F., Zhang, J., Xue, Y. T., and Li, Y. (2021). To explore the mechanism and equivalent molecular group of radix astragali and semen Lepidii in treating heart failure based on network pharmacology. *Evid. Based Complement. Altern. Med.* 2021, 5518192. doi:10.1155/2021/5518192

Yu, Y., Spatz, E. S., Tan, Q., Liu, S., Lu, Y., Masoudi, F. A., et al. (2019). Traditional Chinese medicine use in the treatment of acute heart failure in western medicine hospitals in China: analysis from the China PEACE retrospective heart failure study. *J. Am. Heart Assoc.* 8 (15), e012776. doi:10.1161/aha.119.012776

Yuan, C. C., Kazmierczak, K., Liang, J. S., Zhou, Z. Q., Yadav, S., Gomes, A. V., et al. (2018). Sarcomeric perturbations of myosin motors lead to dilated cardiomyopathy in genetically modified MYL2 mice. *Proc. Natl. Acad. Sci. U. S. A.* 115 (10), E2338–E2347. doi:10.1073/pnas.1716925115

Zang, Y. B., Wan, J. J., Zhang, Z., Huang, S., Liu, X., Zhang, W. D., et al. (2020). An updated role of astragaloside IV in heart failure. *Biomed. Pharmacother.* 126, 110012. doi:10.1016/j.biopha.2020.110012

Zhang, S., Tang, F., Yang, Y., Lu, M., Luan, A., Zhang, J., et al. (2015). Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis. *PLoS One* 10 (3), e0118759. doi:10.1371/journal.pone.0118759

Zhou, X. M., Xue, H. G., Wang, L. B., Zhao, Y. J., Chai, H., Zhang, J., et al. (2016). Total flavonoids of Astragalus plays a cardioprotective role in viral myocarditis. *Acta Cardiol.* 31 (2), 81–88. doi:10.6515/ac20150242h

Zhu, L. M., Vranckx, R., Van Kien, P. K., Lalande, A., Boisset, N., Mathieu, F., et al. (2018). Perindopril improves cardiac function by enhancing the expression of SIRT3 and PGC-1 alpha in a rat model of isoproterenol-induced cardiomyopathy. *Front. Pharmacol.* 11, 94. doi:10.3389/fphar.2020.00094